Logo

Japanese Proteomics Consortium Will Use Biacore System

Jul 08, 2002

NEW YORK, July 8-A Japanese pharmaceutical development consortium will use Biacore's newest system for analyzing drug/protein interactions, the company said today.

 

The Reverse Proteomics Research Institute consortium, which includes 11 Japanese pharmaceutical companies, was founded in May 2001. It is currently engaged in a project to study the interactions between 800 small molecules and 6,000 cDNA-derived human proteins. The effort is funded by the member companies and by the Japanese economic ministry.

 

The Biacore system, S51, supplies data on binding kinetics, drug/target affinity, and reaction specificity for lead optimization and pre-clinical drug candidate studies.

 

Biacore, which develops tools for life science research, is based in Uppsala, Sweden.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.